Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and for cancer supportive care by targeting high value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancers and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizerâs palbociclib (IbranceÂŽ) for the treatment of MDM2-amplified advanced solid cancers, and in an upcoming Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Emerging ALRN-6924 clinical and substantial preclinical data support its use across multiple cancer types as a combination therapy with targeted agents, chemotherapies, and immuno-oncology drugs. Aileron Therapeutics is exploring collaboration opportunities regarding ALRN-6924 and for its research in areas such as targeted protein degradation, HIF1-Îą, and the Bcl-2 family of cancer targets. Source
No articles found.
NextGen Healthcare, Inc. provides a range of software, services, and analytics sol...
NextGen Healthcare, Inc. provides a range of so...
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...
Cellectis is a clinical-stage biopharmaceutical...
Coherus BioSciences is a leading biosimilar company that develops and commercializ...
Coherus BioSciences is a leading biosimilar com...
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing an...
Aeterna Zentaris is a specialty biopharmaceutic...
Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...
Exicure, Inc. is a clinical stage biotechnology...
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused ...
DiaMedica Therapeutics Inc. is a clinical stage...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Join the National Investor Network and get the latest information with your interests in mind.